Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiratricol withdrawal versus continuation in males with MCT8 deficiency
NL-OMON59689Phase 3Completed
- Sponsor
- Egetis Therapeutics
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Allan-Herndon-Dudley syndrome (AHDS) comparing Continue tiratricol with Withdraw tiratricol / placebo (2 arms). Primary endpoints: Rate of change from baseline in serum total T3 during the 30-day randomized treatment period and Proportion meeting rescue criterion during the 30-day randomized treatment period. Started Jul 2023; status: completed.
02
Drugs
tiratricol
03
Conditions
Allan-Herndon-Dudley syndrome (AHDS)
Beyond the preview
Go deeper on NL-OMON59689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59689.